Modulation of hematopoietic colony formation of stem cells in peripheral blood by anti-TGF-beta in patients with severe immunosuppression. NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


Modulation of hematopoietic colony formation of stem cells in peripheral blood by anti-TGF-beta in patients with severe immunosuppression.

Klin Wochenschr. 1990 Dec 30;69(24):1139-45. Unique Identifier : AIDSLINE MED/92236049
Harms B; Kogler G; Wernet P; Bruster HT; Schneider EM; Institut fur Blutgerinnung und Transfusionsmedizin, Heinrich; Heine Universitat, Dusseldorf.

Abstract: The influence of transforming growth factor-beta (TGF-beta) on hematopoiesis has been evaluated by adding blocking antibodies against TGF-beta to colony forming assays (CFU-c). When optimum concentrations of recombinant growth factors, granulocyte-macrophage colony stimulating factor (GM-CSF), and interleukin-3 (IL-3) were added to stem cells from the peripheral blood of healthy individuals and certain patients with tumors or HIV infection, the anti-TGF-beta capable of blocking 5 ng/ml of active TGF-beta had no significant influence on erythroid or myeloid colony formation. However, in certain immunosuppressed individuals, anti-TGF-beta resulted in a significant decrease of erythroid colony formation and slight suppression of myeloid colony formation. The significant inhibition of hematopoiesis by plasma of HIV patients could be due to the presence of active forms of TGF-beta. The results of the blocking experiments are consistent with the concept that TGF-beta in low concentrations is essential for erythropoiesis and myelopoiesis but that higher levels of TGF-beta primarily inhibit erythropoiesis in vitro. TGF-beta serves as a coordinating factor when efficient recruitment of granulocytes and monocytes is more essential than erythropoiesis and stem cell growth.
Keywords: *Colony-Forming Units Assay Fibrosarcoma/BLOOD Hematopoietic Stem Cells/*PHYSIOLOGY Human HIV Seropositivity/BLOOD Immunocompromised Host/*PHYSIOLOGY Sarcoma, Ewing's/BLOOD Transforming Growth Factor beta/*ANTAGONISTS & INHIB/PHYSIOLOGY JOURNAL ARTICLEKWDcolony-formingunitsassayfibrosarcoma/bloodhematopoieticstemcells/KWDphysiologyhumanhivseropositivity/bloodimmunocompromisedhost/KWDphysiologysarcoma,ewing's/bloodtransforminggrowthfactorbeta/KWDantagonists&inhib/physiologyjournalarticle
920730
M9271074

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .